Caricamento...
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Lung cancer is the leading cause of cancer death in the United States. The vast majority of patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5%. After first-line chemotherapy or biomarker-matched targeted therapy, only suitable for a small group of patients, fu...
Salvato in:
| Pubblicato in: | Ther Adv Med Oncol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066544/ https://ncbi.nlm.nih.gov/pubmed/27800034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016661164 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|